Phase 2/3 VALO Study: Frequently Asked Questions

“Do I get paid for being in the study?”
Yes, you are paid for your time and effort. The amount is up to $1,200 if all visits and assessments are completed.

“How can I participate if I can’t take time off of work to travel to clinic visits?”
At the end of September 2019, a new site opened that can see VALO patients on the weekends. If you would like to participate at this site, you can contact PC Project.

“Does the study provide financial reimbursement for babysitting?”
Yes, the study provides reimbursement for respite care (care for children, spouse, seniors, animals, etc.). You will have to provide receipts or documentation.

“The nearest site is 3 hours away, too short to fly. What if I can’t drive, don’t want to drive and/or don’t have someone to drive me?”
The study provides transportation to and from the clinical site for you and a companion. In this case, a car and driver would be provided to you to assist with the round trip. The study also provides financial support for transportation (train, bus, gas mileage, tolls, airfare), lodging and other costs incurred as a result of study participation.

“How can I find out if I might be taking a medication that I can’t take during the study?”
First, don’t stop any medications that have previously been approved by your doctor. If you are interested in participating, please contact PC Project so they can connect you with a clinical trial clinician that can answer your questions to see if you are a candidate for the study.

“When will study enrollment close?”
Study enrollment may close as early as the end of 2019….but we need more patients! Please complete the short form at https://www.surveygizmo.com/s3/4854812/Phase2-3, if you are interested in participating to get started.

“What if the study drug works for me during the study, can I still take it after I finish the study?”
An extension study will be opening at the beginning of 2020, which will allow any patient that received study drug in the VALO study, and the patient and clinician believed helped the patient, to continue to use experimental PTX-022 (QTORIN™ topical rapamycin). The study drug will be provided at no cost to the patient.

For more info:
valostudy.org
Clinicaltrials.gov
NCT03920228

Get Started
If you want to participate, complete the form at
surveygizmo.com/s3/4854812/Phase2-3
or contact PC Project:
801-987-8758
info@pachyonychia.org